bromocriptine has been researched along with Heart Valve Diseases in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (64.29) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Clausen, MF; Fosbøl, E; Gislason, G; Kristensen, SL; Køber, L; Rørth, R; Torp-Pedersen, C; Weeke, PE; Westergaard, LM | 1 |
| Arastu, MI; Curiale, AM; Lipton, BA; Longo, S; Nanda, S; Tessier, S | 1 |
| Au, WL; Chan, YH; Lee, RK; Ng, KK; Tan, LC; Tan, NC | 1 |
| Doi, K; Isono, T; Kawamura, T; Kitagawa, N; Kuno, S; Masaki, M; Mizuta, E; Oeda, T; Sawada, H; Taniguchi, S; Yaku, H; Yamamoto, K; Yutani, C | 1 |
| Andersohn, F; Garbe, E | 1 |
| Martin, NM; Meeran, K; Tan, T | 1 |
| Pullan, PT | 1 |
| Azevedo, M; Boguszewski, CL; de Souza, AM; dos Santos, CM; Marini, LC; Sakamoto, KS | 1 |
| Elenkova, A; Kalinov, K; Shabani, R; Zacharieva, S | 1 |
| Bilge, A; Kurtulmus, N; Yarman, S | 1 |
| Baran, AS; Rack, MJ; Richert, AC; Roffwarg, HP | 1 |
| Basu, S; Chaudhuri, KR; Dhawan, V; Jackson, G; Odin, P | 1 |
| Chung, EJ; Kim, JY; Lee, WY; Park, SW | 1 |
| Burger, E; Härtter, S; Kvernmo, T | 1 |
1 review(s) available for bromocriptine and Heart Valve Diseases
| Article | Year |
|---|---|
A review of the receptor-binding and pharmacokinetic properties of dopamine agonists.
Topics: Animals; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Heart Valve Diseases; Humans; Indoles; Pergolide; Pulmonary Fibrosis; Receptors, Dopamine | 2006 |
13 other study(ies) available for bromocriptine and Heart Valve Diseases
| Article | Year |
|---|---|
Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine.
Topics: Adult; Age Factors; Bromocriptine; Case-Control Studies; Comorbidity; Denmark; Dopamine Agonists; Female; Heart Valve Diseases; Humans; Hyperprolactinemia; Incidence; Registries; Risk Assessment; Risk Factors; Sex Factors; Time Factors | 2021 |
Long-term low-dose cabergoline usage: Another association with cardiac valvulopathy.
Topics: Bromocriptine; Cabergoline; Ergolines; Heart Valve Diseases; Humans; Middle Aged; Pituitary Neoplasms | 2023 |
Bromocriptine use and the risk of valvular heart disease.
Topics: Aged; Aortic Valve Insufficiency; Bromocriptine; Dopamine Agonists; Dose-Response Relationship, Drug; Echocardiography, Doppler; Female; Heart Valve Diseases; Humans; Male; Mitral Valve Insufficiency; Parkinson Disease; Receptor, Serotonin, 5-HT2B; Risk Factors; Severity of Illness Index; Tricuspid Valve Insufficiency | 2009 |
High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease.
Topics: Age Factors; Aged; Benzothiazoles; Bromocriptine; Cabergoline; Case-Control Studies; Dopamine Agonists; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Hypertension; Male; Parkinson Disease; Pergolide; Pramipexole; Risk Factors | 2009 |
Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists.
Topics: Aged; Aged, 80 and over; Apomorphine; Benzothiazoles; Bromocriptine; Cabergoline; Databases, Factual; Dopamine Agonists; Endomyocardial Fibrosis; Ergolines; Female; Fibrosis; Heart Valve Diseases; Humans; Indoles; Male; Middle Aged; Pergolide; Pericarditis; Pleural Diseases; Pramipexole; Pulmonary Fibrosis; Retroperitoneal Fibrosis; Tetrahydronaphthalenes; Thiophenes; United States | 2009 |
Dopamine agonists and hyperprolactinaemia.
Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia | 2009 |
Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy.
Topics: Antiparkinson Agents; Bromocriptine; Cabergoline; Case-Control Studies; Cross-Sectional Studies; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Hyperprolactinemia; Male; Parkinson Disease; Pergolide; Prolactin; Serotonin 5-HT2 Receptor Agonists; Ultrasonography | 2009 |
A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Prolactinoma | 2012 |
Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment.
Topics: Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Case-Control Studies; Dopamine Agonists; Echocardiography; Ergolines; Female; Fibrosis; Heart Valve Diseases; Heart Valves; Humans; Male; Middle Aged; Pituitary Neoplasms; Prevalence; Prolactinoma; Prospective Studies | 2012 |
Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas.
Topics: Adult; Aged; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Pituitary Neoplasms; Prevalence; Prolactinoma; Retrospective Studies; Risk Factors; Ultrasonography; Young Adult | 2012 |
Cardiopulmonary complications of ergot-derivative dopamine agonists.
Topics: Antipsychotic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia; Pergolide; Pulmonary Fibrosis; Risperidone | 2004 |
Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared.
Topics: Aortic Valve; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Fibrosis; Heart Valve Diseases; Humans; Parkinson Disease; Pergolide | 2004 |
Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists.
Topics: Adult; Aged; Aged, 80 and over; Bromocriptine; Dopamine Agonists; Echocardiography; Ergot Alkaloids; Heart Valve Diseases; Humans; Middle Aged; Parkinson Disease; Pergolide; Reference Values | 2006 |